These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 10694563)

  • 1. Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma.
    Levitan N; Dowlati A; Shina D; Craffey M; Mackay W; DeVore R; Jett J; Remick SC; Chang A; Johnson D
    J Clin Oncol; 2000 Mar; 18(5):1102-9. PubMed ID: 10694563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.
    Glisson BS; Kurie JM; Perez-Soler R; Fox NJ; Murphy WK; Fossella FV; Lee JS; Ross MB; Nyberg DA; Pisters KM; Shin DM; Hong WK
    J Clin Oncol; 1999 Aug; 17(8):2309-15. PubMed ID: 10561292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
    J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer.
    Bremnes RM; Sundstrøm S; Vilsvik J; Aasebø U;
    J Clin Oncol; 2001 Aug; 19(15):3532-8. PubMed ID: 11481360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
    Bunn PA; Kelly K
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-144-S12-148. PubMed ID: 9331140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
    Lu C; Komaki R; Lee JS; Shin DM; Palmer JL; Coldman BJ; Pisters KM; Kurie JM; Fossella FV; Glisson BS
    Clin Cancer Res; 2003 Jun; 9(6):2085-91. PubMed ID: 12796372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
    Kakolyris S; Agelidou A; Androulakis N; Tsaroucha E; Kouroussis Ch; Agelidou M; Karvounis N; Veslemes M; Christophylakis Ch; Argyraki A; Geroyianni A; Georgoulias V
    Lung Cancer; 2006 Jul; 53(1):59-65. PubMed ID: 16716447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of up-front accelerated thoracic radiotherapy combined with chemotherapy and optional up-front prophylactic cranial irradiation in limited small-cell lung cancer. Groupe d'Oncologie Thoracique des Régions Alpines.
    Hügli A; Moro D; Mermillod B; Bolla M; Alberto P; Bonnefoi H; Miralbell R
    J Clin Oncol; 2000 Apr; 18(8):1662-7. PubMed ID: 10764426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
    Garces YI; Okuno SH; Schild SE; Mandrekar SJ; Bot BM; Martens JM; Wender DB; Soori GS; Moore DF; Kozelsky TF; Jett JR
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):995-1001. PubMed ID: 17336213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12.
    Glisson B; Scott C; Komaki R; Movsas B; Wagner H
    J Clin Oncol; 2000 Aug; 18(16):2990-5. PubMed ID: 10944132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
    Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
    Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study.
    Le QT; McCoy J; Williamson S; Ryu J; Gaspar LE; Edelman MJ; Dakhil SR; Sides SD; Crowley JJ; Gandara DR;
    Clin Cancer Res; 2004 Aug; 10(16):5418-24. PubMed ID: 15328179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12.
    Komaki R; Swann RS; Ettinger DS; Glisson BS; Sandler AB; Movsas B; Suh J; Byhardt RW
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):342-50. PubMed ID: 15890573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
    Frasci G; Comella P; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Parziale A; Comella G
    J Clin Oncol; 1997 Apr; 15(4):1409-17. PubMed ID: 9193333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group.
    Horn L; Bernardo P; Sandler A; Wagner H; Levitan N; Levitt ML; Johnson DH
    J Thorac Oncol; 2009 Apr; 4(4):527-33. PubMed ID: 19240650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V;
    Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
    Miller AA; Wang XF; Bogart JA; Hodgson LD; Rocha Lima CM; Radford JE; Vokes EE; Green MR;
    J Thorac Oncol; 2007 Jul; 2(7):645-51. PubMed ID: 17607121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.